Therapeutic efficacy and safety of undenatured type II collagen singly or in combination with glucosamine and chondroitin in arthritic dogs

Toxicology Mechanisms and Methods

Volumn 17, Issue 4, 2007, Pages 189-196

  D'Altilio, M ^a   Peal, A ^a   Alvey, M ^a   Simms, C ^a   Curtsinger, A ^a   Gupta, R C ^a   Canerdy, T D ^a   Goad, J T ^a   Bagchi, M ^b,c   Bagchi, D ^b,c  

^a MURRAY STATE UNIVERSITY   (United States)

^b InterHealth Nutraceuticals Inc   (United States)

^c CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chondroitin; Dog Arthritis; Glucosamine; Pain Measurement; UC II

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CHONDROITIN SULFATE; COLLAGEN TYPE 2; CREATININE; GLUCOSAMINE; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL LAMENESS; ANIMAL MODEL; ARTHRITIS; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG SAFETY; KIDNEY FUNCTION TEST; LIMB PAIN; LIVER FUNCTION TEST; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; TREATMENT WITHDRAWAL; UREA NITROGEN BLOOD LEVEL;

CANIS FAMILIARIS;

EID: 34247592933     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.1080/15376510600910469     Document Type: Article

References (27)

1. Aceves-Avila, F.J., Medina, F., and Fraga, A. 2001. The antiquity of rheumatoid arthritis: a reappraisal. J. Rheumatol. 28:751-757.
2. Bagchi, D., Misner, B., Bagchi, M., Kothari, S.C., Downs, B.W., and Preuss, H.G. 2002. Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Intl. J. Clin. Pharmacol. Res. 22:101-110.
3. Bellamy, N., Carr, A., Dougados, M., Shea, B., and Wells, G. 2001. Towards a definition of "differences" in osteoarthritis. J. Rheumatol. 28:427-430.
4. Bongartz, T., Sutton, A.J., Sweeting, M.J., Buchan, I., Matteson, E.L., and Montori, V. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 295:2275-2285.
5. Center for Disease Control and Prevention. 1994. Prevalence of disability and associated with health conditions-United States, 1991-1992. MWRW. 4341:737-259.
6. Clegg, D.O., Reda, D.J., Harris, C.L., Klein, M.A., O'Dell, J., Hooper, M.M., Bradley, J.D., Bingham, C.O. III., Weisman, M.H., Jackson, C.G., Lane, N.E., Cush, J.J., Moreland, L.W., Schumacher, H.R., Oddis, C.V., Wolfe, F., Molitor, J.A., Yocum, D.E., Schnitzer, T.J., Furst, D.E., Sawitzke, A.D., Shi, H., Brandt, K.D., Moskowitz, R.W., and Williams, H.J. 2006. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N. Engl. J. Med. 354:795-808.
7. DeParle, L.A., Gupta, R.C., Canerdy, T.D., Goad, J.T., D'Altilio, M., Bagchi, M., and Bagchi, D. 2005. Efficacy and safety of glycosylated undenatured type-II collagen (UC-II) in therapy of arthritic dogs. J. Vet. Pharmacol. Ther. 28:385-390.
8. Eaton, C.B. 2004. Obesity as a risk factor for osteoarthritis: mechanical versus metabolic. Med. Health R I. 87:201-204.
9. Gimsa, U., Sieper, J., Braun, J., and Mitchison, N.A. 1997. Type II collagen serology: a guide to clinical responsiveness to oral tolerance?. Rheumatol. Int. 16:237-240.
10. Goldring, M.B. 2000. Osteoarthritis and cartilage: the role of cytokines. Curr. Rheumatol. Rep. 2:459-465.
11. Helmick, C.G., Lawrence, R.C., Pollard, R.A., Lloyed, E., and Hayes, S.P. 1995. Arthritis and other rheumatoid conditions: who is affected now, will be affected later? National Arthritic Data Workgroup. Arthritic Care Res. 8:203-211.
12. Hielm-Bjorkman, A.K., Kuusela, E., Liman, A., Markkola, A., Saartr, E., Huffuren, P., Leppaluoto, J., Tulano, R.M., and Raekallio, M. 2003. Evaluation of methods for assessment of pain associated with osteoarthritis in dogs. J. Am. Vet. Med. Assoc. 222:1552-1558.
13. Hougee, S., Hartog, A., Sanders, A., Graus, Y.M., Hoijer, M.A., Garssen, J., Van Den Berg, W., van Beuningen, H.M., and Smit, H.F. 2006. Oral administration of the NADPH-oxidase inhibitor apocynin partially restores diminished cartilage proteoglycan synthesis and reduces inflammation in mice. Eur. J. Pharmacol. 531:264-269.
14. Matteson, E.L. 2000. Historical perspective on the classification of vasculitis. Arthritis Care Res. 13:122-127.
15. Mowat, A.M. 1987. The regulation of immune responses to dietary protein antigens. Immunol. Today. 8:93-98.
16. Muhlfeld, A., and Floege, J. 2005. COX-2 inhibitor induced anuric renal failure in a previously healthy young woman. Clin. Nephrol. 63:221-224.
17. Okada, Y. 2000. Pathoetiology of chronic rheumatoid arthritis-from inflammation to bone destruction. From viewpoint of pathology. Nppon Naika Gakkai Zassi. 89:2072-2080.
18. Paroli, E., Antonilli, L., and Biffoni, M. 1991. A pharmacological approach to glycosaminoglycans. Drugs Exptl. Clin. 18:335-343.
19. Peat, G., McCarney, R., and Croft, P. 2001. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann. Rheum. Dis. 60:91-97.
20. Physicians Desk Reference. 1998. 52 nd ed.Medical Economics Company Inc., Montvale, NJ, USA.
21. Richardson, D.C., Schoenherr, W.D., and Zicker, S.C. 1997. Nutritional management of osteoarthritis. Vet. Clin. North Am. Small Anim. Pract. 27:883-911.
22. Sieper, J., Kary, S., Sorensen, H., Alten, R., Eggens, U., Huge, W., Hiepe, F., Kuhne, A., Listing, J., Ulbrich, N., Braun, J., Zink, A., and Mitchison, N. 1996. Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheumatol. 39:41-51.
23. Trentham, D.E. 1998. Oral tolerization as a treatment of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 24:525-536.
24. Trentham, D.E., Dynesius-Trentham, R.A., Orav, E.J.., Bagchi, M., Kothari, S., Pruess, H.G., and Bagchi, D. 1993. Effects of oral administration of type-II collagen on rheumatoid arthritis. Science 261:1727-1730.
25. Trentham, D.E., Halpner, A.D., Trentham, R.A., Combitche, D., Lorenzo, C., Sewell, K.L., Haflir, D.A., and Weiner, H.L. 2001. Use of undenatured type-II collagen in the treatment of rheumatoid arthritis. Clin. Pract. Alter. Med. 2:254-259.
26. Weiner, H.L. 1997. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol. Today. 18:335-343.
27. Weiner, H.L., Friedman, A., Miller, A., Khoury, S.J., Al-Sabbagh, A., Santosh, L., Sayegh, M., Nussenblatt, R.B., Trentham, D.E., and Hafler, D.A. 1994. Oral tolerance: immunological mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Ann. Rev. Immunol. 12:809-837.